Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naxitamab + sacituzumab govitecan
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of naxitamab, a humanized monoclonal antibody targeting the ganglioside GD2, and sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC). Naxitamab binds to GD2 on the surface of tumor cells, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Sacituzumab govitecan consists of a humanized monoclonal antibody (hRS7) that targets Trop-2, conjugated via a hydrolyzable linker to SN-38, a topoisomerase I inhibitor. The combination is being evaluated in a Phase I/II clinical trial led by M.D. Anderson Cancer Center for patients with metastatic triple-negative breast cancer (TNBC), specifically targeting tumors that express GD2. This approach aims to leverage the targeted delivery of cytotoxic SN-38 alongside the immune-mediated antitumor activity of naxitamab.
- Brand names
- Danyelza + Trodelvy
- Other names
- naxitamab-gqgk + sacituzumab govitecan-hziy
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)GD2TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on naxitamab + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naxitamab + sacituzumab govitecan.